Core Insights - BillionToOne Inc. successfully raised $273.1 million in an upsized US initial public offering despite the ongoing US government shutdown, which has complicated the listing process [1][4]. Company Overview - The company, based in Menlo Park, California, sold 4.55 million shares at $60 each, exceeding the initially marketed range of $49 to $55 for 3.85 million shares [2]. - Following the IPO, BillionToOne's market value is estimated to be over $2.6 billion, with co-founders holding 64% of the voting power [3]. Financial Performance - For the six months ending June 30, BillionToOne reported a net loss of $4.2 million on revenue of $125.5 million, an improvement from a net loss of $15.2 million on revenue of $69.1 million during the same period the previous year [5]. Product Offerings - The company specializes in precision diagnostics, with its flagship product, Unity Complete, being a non-invasive prenatal screening test. Additionally, it offers NorthStar liquid biopsy tests that can detect tumor mutations [5]. Investor Information - Major investors include Hummingbird Ventures, which is expected to hold 19.9% of Class A shares post-IPO, Neotribe Ventures with 11%, and Libertus Capital with 9% [6]. - The IPO is being led by JPMorgan Chase & Co., Piper Sandler Cos., Jefferies Financial Group Inc., and William Blair & Co. The shares are expected to begin trading on the Nasdaq Global Select Market under the symbol BLLN [6].